Answers are grounded in this paper and cite their sources.
Systematic assessment shows microplastic contamination in oral pharmaceuticals for children and pregnant women, indicating significant health risks.
Microplastics (MPs) are pervasive environmental pollutants, with pharmaceuticals emerging as a critical yet under-investigated human exposure pathway, this study systematically assessed MPs contamination in five oral formulations intended for vulnerable populations: starch-based capsules, enteric-coated capsules, hydroxypropyl methylcellulose capsules, and two pediatric vitamin AD soft capsules. Using Laser Direct Infrared Spectroscopy (LDIR), pyrolysis gas chromatography-mass spectrometry (Py-GC/MS), and scanning electron microscopy (SEM), we detected MPs in all products.. LDIR identified particles of 20 - 286 µm comprising PE, PVC, PS, PP, PET, and synthetic rubbers, with contamination profiles varying significantly by dosage forms. Quantitative Py-GC/MS analysis quantified PE, PS, PVC, and PP. SEM revealed morphological evidence of particles, from film-like PP to fibrous PET. Notably, starch-based capsules showed no MPs at a confidence threshold ≥0.8, whereas pediatric soft capsules contained the highest diversity (12–16 polymer types, up to 156 particles per sample). This This first systematic evidence that oral pharmaceuticals—especially those for pregnant women and children—are a direct, overlooked MPs exposure pathway underscores an urgent need to integrate MPs monitoring into pharmaceutical quality control.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: